Publications by Ole Petter Børmer
73 publications found
Original articles
Reference intervals for carcinoembryonic antigen (CEA), CA125, MUC1, Alfa-foeto-protein (AFP), neuron-specific enolase (NSE) and CA19.9 from the NORIP study
Scand J Clin Lab Invest, 68 (8), 703-13
DOI 10.1080/00365510802126836, PubMed 18609108
Human heterophilic antibodies display specificity for murine IgG subclasses
Clin Biochem, 38 (5), 465-72
DOI 10.1016/j.clinbiochem.2005.02.008, PubMed 15820778
Use of an in vivo biotinylated single-chain antibody as capture reagent in an immunometric assay to decrease the incidence of interference from heterophilic antibodies
Clin Chem, 51 (5), 830-8
DOI 10.1373/clinchem.2004.046979, PubMed 15718486
Pharmaceutical-grade albumin: impaired drug-binding capacity in vitro
BMC Clin Pharmacol, 4, 4
DOI 10.1186/1472-6904-4-4, PubMed 15046641
Testing and validating a homogeneous immunometric assay for interference
Clin Chem Lab Med, 42 (2), 208-14
DOI 10.1515/CCLM.2004.038, PubMed 15061363
A single-chain-Fv-based immunofluorometric assay specific for the CEA variant NCA-2
J Immunol Methods, 283 (1-2), 125-39
DOI 10.1016/j.jim.2003.08.018, PubMed 14659905
Long-term renal function after treatment for malignant germ-cell tumours
Ann Oncol, 13 (2), 222-8
DOI 10.1093/annonc/mdf048, PubMed 11885998
Immunometric assay interference: incidence and prevention
Clin Chem, 48 (4), 613-21
PubMed 11901059
Protein epitopes in carcinoembryonic antigen. Report of the ISOBM TD8 workshop
Tumour Biol, 23 (4), 249-62
DOI 10.1159/000067255, PubMed 12499780
[Prophylactic thyroidectomy in carriers of RET oncogene mutation carriers]
Tidsskr Nor Laegeforen, 120 (27), 3249-52
PubMed 11187163
Automated albumin method underestimates pharmaceutical-grade albumin in vivo
Clin Chem, 45 (7), 1082-4
PubMed 10388486
Epitope mapping and affinity estimation of 83 antibodies against prostate-specific antigen
Tumour Biol, 20 Suppl 1, 52-69
DOI 10.1159/000056531, PubMed 10628410
Stability of free and total prostate specific antigen in serum from patients with prostate carcinoma and benign hyperplasia
J Urol, 159 (5), 1599-605
DOI 10.1097/00005392-199805000-00051, PubMed 9554362
Fecal calprotectin concentration in patients with colorectal carcinoma
Dis Colon Rectum, 41 (3), 316-21
DOI 10.1007/BF02237485, PubMed 9514426
Specificity and affinity of 30 monoclonal antibodies against alpha-fetoprotein
Tumour Biol, 19 (4), 293-300
DOI 10.1159/000030021, PubMed 9679741
[Tumor marker analyses--valuable tools if used correctly]
Tidsskr Nor Laegeforen, 114 (28), 3317-20
PubMed 7809890
Evaluation of serum CA 125 level as a tumor marker in borderline tumors of the ovary
Int J Gynecol Cancer, 3 (5), 299-303
DOI 10.1046/j.1525-1438.1993.03050299.x, PubMed 11578361
Is serum CA 125 at the time of relapse a prognostic indicator for further survival prognosis in patients with ovarian cancer?
Gynecol Oncol, 49 (1), 3-7
DOI 10.1006/gyno.1993.1076, PubMed 8482556
Serum CA 125 level allows early identification of nonresponders during induction chemotherapy
Gynecol Oncol, 49 (1), 73-9
DOI 10.1006/gyno.1993.1089, PubMed 8482563
Serum CA 125 as a tumor marker and the expression of c-erbB-2 oncogene in tubal malignancies
Int J Gynecol Cancer, 3 (2), 116-121
DOI 10.1046/j.1525-1438.1993.03020116.x, PubMed 11578331
Serum carcinoembryonic antigen in relation to survival, DNA ploidy pattern, and recurrent disease in 406 colorectal carcinoma patients
Scand J Gastroenterol, 27 (12), 1061-8
DOI 10.3109/00365529209028139, PubMed 1475624
Circulating secretory component in relation to early diagnosis and treatment of liver metastasis from colorectal carcinomas
J Clin Pathol, 45 (7), 568-71
DOI 10.1136/jcp.45.7.568, PubMed 1517455
Prognostic value of pre- and postoperative serum CA 125 levels in ovarian cancer: new aspects and multivariate analysis
Obstet Gynecol, 79 (6), 1002-10
PubMed 1579296
CA 125 measured before second-look laparotomy is an independent prognostic factor for survival in patients with epithelial ovarian cancer
Gynecol Oncol, 45 (3), 323-8
DOI 10.1016/0090-8258(92)90313-8, PubMed 1612511
Specificity and affinity of monoclonal antibodies against carcinoembryonic antigen
Cancer Res, 52 (8), 2329-39
PubMed 1559235
CA125 in peritoneal fluid of ovarian cancer patients
Gynecol Oncol, 44 (2), 161-5
DOI 10.1016/0090-8258(92)90032-e, PubMed 1544593
Carcinoembryonic antigen in anal carcinoma
Acta Oncol, 31 (3), 333-5
DOI 10.3109/02841869209108181, PubMed 1622654
CA125 and placental alkaline phosphatase as serum tumor markers in epithelial ovarian carcinoma
Tumour Biol, 13 (3), 168-74
DOI 10.1159/000217761, PubMed 1626181
Tumour markers as seen from the clinical laboratory: physiological, biochemical, and analytical aspects
Scand J Clin Lab Invest Suppl, 206, 12-20
DOI 10.3109/00365519109107721, PubMed 1947756
Epitope group specificity of six immunoassays for carcinoembryonic antigen
Tumour Biol, 12 (1), 9-15
DOI 10.1159/000217682, PubMed 1705049
Cyclical use of tamoxifen and high-dose medroxyprogesterone acetate in advanced estrogen receptor positive breast cancer
Breast Cancer Res Treat, 17 (1), 45-50
DOI 10.1007/BF01812683, PubMed 2151369
Distribution of the carcinoembryonic antigen CEA in gastric lesions. Immunohistochemical testing of three novel monoclonal antibodies
Histol Histopathol, 5 (2), 199-204
PubMed 2134373
Selection of monoclonal antibodies for use in an immunometric assay for carcinoembryonic antigen
J Immunol Methods, 127 (2), 171-8
DOI 10.1016/0022-1759(90)90066-5, PubMed 1690245
Unexpectedly high serum methotrexate levels in cystectomized bladder cancer patients with an ileal conduit treated with intermediate doses of the drug
J Urol, 143 (3), 498-501
DOI 10.1016/s0022-5347(17)40001-2, PubMed 2304161
Immunometric assay by flow cytometry using mixtures of two particle types of different affinity
J Immunol Methods, 126 (2), 183-9
DOI 10.1016/0022-1759(90)90149-p, PubMed 2303729
Carcinoembryonic antigen in medullary thyroid carcinoma: an immunohistochemical study applying six novel monoclonal antibodies
Mod Pathol, 2 (6), 610-7
PubMed 2587568
Antigenic sites in carcinoembryonic antigen
Cancer Res, 49 (17), 4852-8
PubMed 2474375
Interference of complement with the binding of carcinoembryonic antigen to solid-phase monoclonal antibodies
J Immunol Methods, 121 (1), 85-93
DOI 10.1016/0022-1759(89)90423-7, PubMed 2502577
[Treatment of diffuse malignant mesothelioma of the pleura]
Tidsskr Nor Laegeforen, 108 (33), 3091-3
PubMed 3206498
An immunocytochemical method for assaying oestrogen receptors in breast cancers. A comparison with the steroid binding assay
Histol Histopathol, 3 (3), 269-74
PubMed 2980233
Evaluation of serum CA 125 levels in the monitoring of ovarian cancer
Am J Obstet Gynecol, 157 (1), 88-92
DOI 10.1016/s0002-9378(87)80352-6, PubMed 2440307
Primary breast cancer. Flow cytometric DNA pattern in relation to clinical and histopathologic characteristics
Cancer, 57 (4), 808-11
DOI 10.1002/1097-0142(19860215)57:4<808::aid-cncr2820570421>3.0.co;2-#, PubMed 3943014
Estrogen receptors and long-term prognosis in breast cancer
Cancer, 53 (11), 2525-9
DOI 10.1002/1097-0142(19840601)53:11<2525::aid-cncr2820531126>3.0.co;2-8, PubMed 6713348
Estrogen and progesterone receptors in normal and malignant vulvar tissue
Gynecol Obstet Invest, 17 (6), 281-3
DOI 10.1159/000299164, PubMed 6745735
Serum lactate dehydrogenase (S-LDH) and S-LDH isoenzymes in patients with testicular germ cell tumors
Mol Gen Genet, 189 (2), 326-33
DOI 10.1007/BF00337825, PubMed 6190072
[Hormonal treatment of breast cancer in men. Experiences with antiestrogen Tamoxifen]
Tidsskr Nor Laegeforen, 102 (34-36), 1849-51
PubMed 7170693
[Clinical significance of steroid hormone receptors in breast cancer]
Tidsskr Nor Laegeforen, 102 (34-36), 1866-8
PubMed 7170700
Nuclear feulgen DNA content and nuclear size in human breast carcinoma
Hum Pathol, 13 (7), 626-30
DOI 10.1016/s0046-8177(82)80004-x, PubMed 7084938
A direct assay for carcinoembryonic antigen in serum and its diagnostic value in metastatic breast cancer
Clin Biochem, 15 (3), 128-32
DOI 10.1016/s0009-9120(82)90543-4, PubMed 7116619
[Toxicity of high-dose methotrexate therapy]
Tidsskr Nor Laegeforen, 99 (33), 1708-11
PubMed 531854
[Spectrum analysis--an evaluation of quality]
Tidsskr Nor Laegeforen, 99 (32), 1655-6
PubMed 531845
Isotope nephrography in carcinoma of the uterine cervix stage I B
Acta Radiol Ther Phys Biol, 16 (3), 219-23
DOI 10.3109/02841867709133939, PubMed 906891
ISOTOPE NEPHROGRAPHY IN CARCINOMA OF UTERINE CERVIX STAGE-IB
ACTA RADIOL THER PHY, 16 (3), 219-223
Purification of a cytotoxic factor from human and rat tissues
Br J Cancer, 34 (4), 359-67
DOI 10.1038/bjc.1976.178, PubMed 987795
[Postoperative fluid therapy. A combination of "Normodex" and glucose-saline solution]
Tidsskr Nor Laegeforen, 94 (23), 1385-7
PubMed 4410452
Review articles
Immunoassays for carcinoembryonic antigen: specificity and interferences
Scand J Clin Lab Invest, 53 (1), 1-9
DOI 10.3109/00365519309092525, PubMed 7680822
Other articles
The war on heterophilic antibody interference
Clin Chem, 51 (1), 9-11
DOI 10.1373/clinchem.2004.042994, PubMed 15613705
Tumor markers in an evidence-based medicine
Scand J Clin Lab Invest, 61 (6), 417-9
DOI 10.1080/00365510152567040, PubMed 11681530
Summary report of the TD-3 workshop: characterization of 83 antibodies against prostate-specific antigen
Tumour Biol, 20 Suppl 1, 1-12
DOI 10.1159/000056523, PubMed 10628402
[Follow-up after colorectal cancer. Undeserved neglect of CEA-analysis]
Tidsskr Nor Laegeforen, 118 (18), 2825-6
PubMed 9748821
Specificity and affinity of 26 monoclonal antibodies against the CA 125 antigen: first report from the ISOBM TD-1 workshop. International Society for Oncodevelopmental Biology and Medicine
Tumour Biol, 17 (4), 196-219
DOI 10.1159/000217982, PubMed 8685601
Immunohistochemical characterization of 22 monoclonal antibodies against the CA125 antigen: 2nd report from the ISOBM TD-1 Workshop
Tumour Biol, 17 (6), 325-31
PubMed 8938947
[Prostate-specific antigen and prostatic cancer]
Tidsskr Nor Laegeforen, 114 (6), 710-1
PubMed 7514820
From tissue polypeptide antigen to specific cytokeratin assays
Tumour Biol, 15 (4), 185-7
DOI 10.1159/000217891, PubMed 7524129
Major disagreements between immunoassays of carcinoembryonic antigen may be caused by nonspecific cross-reacting antigen 2 (NCA-2)
Clin Chem, 37 (10 Pt 1), 1736-9
PubMed 1914175
Standardization, specificity, and diagnostic sensitivity of four immunoassays for carcinoembryonic antigen
Clin Chem, 37 (2), 231-6
PubMed 1993329
Relative bioavailability of oral low dose methotrexate. A comparison of 2 different formulations
Eur J Clin Pharmacol, 34 (5), 517-9
DOI 10.1007/BF01046713, PubMed 3203714
CLINICAL UTILITY OF TUMOR-MARKERS
Scand. J. Clin. Lab. Invest., 47 (3), 301-302
PROGESTERONE RECEPTORS AS A PROGNOSTIC FACTOR IN STAGE-II BREAST-CANCER
N. Engl. J. Med., 310 (20), 1324-1325
Phase II study of tamoxifen in patients with metastatic malignant melanoma
Cancer Treat Rep, 66 (6), 1437
PubMed 7083247
Books
Transfusjonshåndbok: aktuelle produkter, indikasjoner, transfusjonsprosedyrer,komplikasjoner
Blodbanken i Oslo, [Oslo] ([Rev. utg.]), 43 s.
BIBSYS 031826296
Transfusjonshåndbok: aktuelle produkter, indikasjoner, transfusjonsprosedyrer,komplikasjoner
Blodbanken, [Oslo], 44 s.
BIBSYS 972481192
Theses
Immunoassays for carcinoembryonic antigen: specificity and interferences
Central Laboratory, The Norwegian Radium Hospital and Norwegian Cancer Society, [Oslo], 1 b. (flere pag.)
BIBSYS 920420125, ISBN 82-7633-014-2